10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Aspira Womens Health's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was 6,749.32%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Aspira Womens Health's 10-Year ROIIC % or its related term are showing as below:
FRA:CUL's 10-Year ROIIC % is ranked better than 99.52% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.17
vs FRA:CUL: 6749.32
Aspira Womens Health 10-Year ROIIC % Historical Data
The historical data trend for Aspira Womens Health's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aspira Womens Health's 10-Year ROIIC %
For the Diagnostics & Research subindustry, Aspira Womens Health's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health's 10-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's 10-Year ROIIC % falls into.
Aspira Womens Health 10-Year ROIIC % Calculation
Aspira Womens Health's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -17.287 (Dec. 2023) - -6.47 (Dec. 2013) )
/
( 1.812 (Dec. 2023) - 1.55 (Dec. 2013) )
=
-10.817
/
0.262
=
-4,128.63%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Aspira Womens Health (FRA:CUL) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Aspira Womens Health 10-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Aspira Womens Health's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Aspira Womens Health (FRA:CUL) Business Description
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:CUL has been successfully added to your 